Publication at First Faculty of Medicine |
2015
Abstract
The inhibitors of sodium-glucose cotransporter (SGLT2) open new era in the treatment of diabetes because they spread the possibilities of treatment based on increased glucose excretion into urine.Besides the effects of other antidiabetic drugs influencing pancreas or target organ for insulin action the SGLT2 inhibition demonstrates thet kidneys are involved into regulation of glucose homeostasis. Empagliflozin represents highly selective inhibitor of this transporter which acts solely in kidneys.